JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.C100160200 on August 23, 2001

J. Biol. Chem., Vol. 276, Issue 42, 38337-38340, October 19, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/42/38337    most recent
C100160200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tobe, K.
Right arrow Articles by Kadowaki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tobe, K.
Right arrow Articles by Kadowaki, T.

ACCELERATED PUBLICATION
Increased Expression of the Sterol Regulatory Element-binding Protein-1 Gene in Insulin Receptor Substrate-2minus /minus Mouse Liver*

Kazuyuki TobeDagger , Ryo SuzukiDagger , Masashi AoyamaDagger , Toshimasa YamauchiDagger , Junji KamonDagger , Naoto KubotaDagger , Yasuo TerauchiDagger , Junji MatsuiDagger , Yasuo Akanuma§, Satoshi KimuraDagger , Jun Tanaka, Manabu Abe, Jun Ohsumi, Ryozo NagaiDagger , and Takashi KadowakiDagger ||

From the Dagger  Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, § Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, 100-0005, and  Biomedical Research Laboratories, Sankyo Corporation Ltd., Tokyo, 140-8710, Japan

Received for publication, April 3, 2001, and in revised form, August 14, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Insulin receptor substrate (IRS)-2-/- mice develop diabetes because of insulin resistance in the liver and failure to undergo beta -cell hyperplasia. Here we show by DNA chip microarray analysis that expression of the sterol regulatory element-binding protein (SREBP)-1 gene, a downstream target of insulin, was paradoxically increased in 16-week-old IRS-2-/- mouse liver, where insulin-mediated intracellular signaling events were substantially attenuated. The expression of SREBP-1 downstream genes, such as the spot 14, ATP citrate-lyase, and fatty acid synthase genes, was also increased. Increased liver triglyceride content in IRS-2-/- mice assures the physiological importance of SREBP-1 gene induction. IRS-2-/- mice showed leptin resistance; low dose leptin administration, enough to reduce food intake and body weight in wild-type mice, failed to do so in IRS-2-/- mice. Interestingly, high dose leptin administration reduced SREBP-1 expression in IRS-2-/- mouse liver. Thus, IRS-2 gene disruption results in leptin resistance, causing an SREBP-1 gene induction, obesity, fatty liver, and diabetes.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The pathogenesis of type 2 diabetes involves complex interactions among multiple physiological defects. Transgenic and knockout technology to create animal models of type 2 diabetes have had a major impact on assessment of the function of newly identified molecules implicated in the regulation of glucose homeostasis in vivo (1). The insulin receptor substrate (IRS)1 proteins play a key role in signal transduction from the insulin receptor (reviewed in Refs. 2-4). These molecules are major intracellular phosphorylation targets of activated insulin receptor tyrosine kinase. The mammalian IRS protein family contains at least four members, ubiquitous IRS-1 (5) and IRS-2 (6), adipose tissue-predominant IRS-3 (7), and IRS-4, which are expressed in thymus, brain, and kidney (8). The physiological roles of each protein have been evaluated by gene targeting strategies. IRS-1-/- mice are growth-retarded and insulin-resistant (9, 10) but do not develop diabetes, because an alternate substrate IRS-2 (10) or pp190 (11) compensates for the lack of IRS-1 in liver (11) and, at least in part, in skeletal muscle (12). In addition, hyperinsulinemia associated with beta -cell hyperplasia effectively countervailed the insulin-resistant states (13). IRS-2-/- mice, however, developed diabetes because of inadequate beta -cell proliferation combined with liver-insulin resistance (14-16). Mice lacking IRS-3 or IRS-4 had milder phenotypes (17, 18).

Liver is a major target organ for insulin action, contributing to energy storage in the fed state by regulating catabolic and anabolic pathways. Liver-specific insulin receptor knockout mice exhibit dramatic insulin resistance (19). Insulin decreases gluconeogenic enzyme mRNAs (20) and increases lipogenic enzyme mRNAs. A transcription factor of sterol regulatory element-binding protein 1c (SREBP-1c) (21-23) or adipocyte differentiation and determination factor (24) plays a central role in insulin-mediated lipogenic enzyme induction. Although SREBP-1c expression is up-regulated by insulin and glucose in vitro (22, 23, 25, 26), the in vivo significance of insulin or glucose in SREBP-1c gene up-regulation is a matter of controversy. How SREBP-1c expression is regulated in vitro and in vivo and how SREBP-1c expression is involved in leptin action and insulin resistance have been the focus of intensive research.

Because the organ responsible for insulin resistance in IRS-2-/- mice is the liver (16), we focused our research on the liver and performed a global gene expression study by using oligonucleotide microarrays. We discovered paradoxical SREBP-1c gene induction in insulin-resistant IRS-2-/- mice liver, even in the early euglycemic phase, indicating that neither insulin action nor hyperglycemia was responsible for SREBP-1 gene induction. We provided evidence to show that leptin resistance is causally related to SREBP-1 gene induction. The molecular mechanism, as well as biological relevance, of leptin resistance in the development of type 2 diabetes is discussed.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- All chemicals used were from Sigma. [alpha -32P]dCTP was obtained from PerkinElmer Life Sciences.

Animal Experiments-- IRS-1-/-, IRS-2-/-, and wild-type mice were prepared by heterozygote intercrosses (9, 16). Mice were housed on a 12-h light-dark cycle and were given ad libitum access to regular chow MF consisting of 25% (w/w) protein, 53% carbohydrates, 6% fat, and 8% water (Oriental Yeast Co., Ltd., Osaka, Japan). All experiments in this study were performed on male mice, except when stated specifically that female mice were used.

Body Weight, Weight of Adipose Tissue, and Serum Leptin Levels-- Body weight was assessed between 0900 and 1100 h. The statistical significance of the differences in body mass between groups was determined by Student's t test (two-tailed). The weight of the epididymal fat was measured as described previously (27). Leptin was assayed with the enzyme-linked immunosorbent assay-based Quantikine M mouse leptin immunoassay kit (R & D Systems, Minneapolis, MN) according to the manufacturer's instructions.

Liver Triglyceride and Cholesterol Content-- The triglyceride and cholesterol content of the liver was measured as described previously (28).

Oligonucleotide Microarray Analysis-- Total liver RNA was isolated from 16-week-old wild-type and IRS-2-/- mice after 15 h of fasting by TRIZOL reagent (Life Technologies, Inc.). RNA was analyzed as follows: cDNA and cRNA probe were prepared as described previously (29). Hybridization, washing, and staining of Affymetrix Genechip murine 11K probe arrays were carried out in an Affymetrix hybridization oven and fluidics station according to the Affymetrix technical manual. The arrays were scanned with a Hewlett-Packard confocal laser scanner and visualized using Affymetrix Genechip 3.1 software. The -fold change in expression in mutant mice versus wild-type mice was calculated using Affymetrix Gene Chip 3.1 software.

Northern Blot Hybridization with cDNA Probes-- Northern blot hybridization was carried out as described previously (26, 30-32). The cDNA probes for mouse SREBP-1, human SREBP-2, mouse spot 14, mouse fatty acid synthase, rat ATP citrate-lyase, mouse malic enzyme, and glucokinase were prepared by cloning reverse transcriptase-polymerase chain reaction products from mouse liver RNA into TA cloning vectors (Invitrogen, Carlsbad, CA). The corresponding bands were quantified by exposure of BAS 2000 to the filters to with BAStation software (Fuji Photo Film Co., Ltd., Tokyo, Japan).

Leptin Administration-- Wild-type and IRS-2-/- mice were injected intraperitoneally once a day at 2100 h with control saline or leptin (10 mg/kg/injection) (PeproTech EC Ltd., London, United Kingdom), and daily body mass and food intake were monitored at 0900 and 2100 h (27). The statistical significance of differences in body mass and food intake between groups was determined using Student's t test (two-tailed).

Regulation of SREBP-1 Gene by Leptin-- Leptin (50 mg/kg/injection) or control saline was administered to 6-week-old IRS-2-/- mice at 0900, 1700, and 0100 h. Body weight and food intake were monitored at 0900 and 2100 h. For the experiments of regulation of SREBP-1 gene by leptin, leptin (50 mg/kg/injection) or control saline was administered to IRS-2-/- mice at 0900 h, when fasting began, at 1700, and at 0100 h. Animals were sacrificed at 0900 h the next day by cervical dislocation. The liver was excised, frozen on liquid nitrogen, and maintained at -80 °C until it was processed further.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

IRS-2-/- Mice Showed Increased Adiposity-- During the course of experiment, we found that the amount of body fat per body weight was increased in IRS-2-/- mice (Fig. 1A). The whole growth curve of wild-type and IRS-2-/- mice from 6 to 16 weeks old revealed that IRS-2-/- mice had gained more body weight after 8 weeks of age before the development of diabetes (Fig. 1B). The proportion of the weight of epididymal fat to total body weight was significantly increased in IRS-2-/- mice at the age of 6 weeks before IRS-2-/- mice had more body weight gain than wild-type mice (Fig. 1A). Moreover, the serum leptin level was increased in IRS-2-/- mice (Fig. 1C), suggesting that these mice were leptin-resistant. By contrast, epididymal fat weight as a proportion of body weight and the serum leptin level of IRS-1-/- mice did not differ significantly from the values in wild-type mice (Fig. 1, A and C).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 1.   Increased adiposity in IRS-2-/- mice. A, weight of epididymal fat as a proportion of total body weight was measured in 6- and 16-week-old male wild-type (WT), IRS-1-/-, and IRS-2-/- mice. B, left, growth curve of wild-type and IRS-2-/- mice. Body weight (0900-1100 h) of male wild-type and IRS-2-/- mice was measured from 6- to 16-week-old. Right, body weight (0900-1100 h) was measured in 16-week-old male wild-type, IRS-1-/-, and IRS-2-/- mice. C, serum leptin level was measured in 6-week-old male wild-type, IRS-1-/-, and IRS-2-/- mice. Values are expressed as the mean ± S.E. (n = 5~7), **, p < 0.01 as compared with the wild-type. N.S., difference not significant.

Expression of SREBP-1 and Downstream Target Genes Were Enhanced in IRS-2-/- Mouse Liver According to the Results of DNA Chip Analysis-- To understand the molecular mechanism of the development of diabetes in IRS-2-/- mice, we performed an integrated gene expression study using liver samples. Total RNA was isolated from 16-week-old wild-type, IRS-1-/-, and IRS-2-/- mice and analyzed by murine 11K oligonucleotide microarray (Affymetrix). Among the ~11K genes and expressed sequence tags analyzed, there was detected an increased expression of the two copies of the SREBP-1 gene in the liver from 16-week-old IRS-2-/- mice in the fasted states (Fig. 2A). This result was surprising, because insulin reportedly up-regulates SREBP-1 gene expression whereas insulin-mediated intracellular signaling events, including phosphatidylinositol 3-kinase activation, are decreased substantially in IRS-2-/- mice (16), and because euglycemic-hyperinsulinemic clamp study demonstrated insulin resistance in the liver in IRS-2-/- mice (33). We also found up-regulated expression of several SREBP-1c target genes, including the spot 14, ATP citrate-lyase, fatty acid synthase, and malic enzyme, all of which are involved in fatty acid synthesis (Fig. 2B). All these findings were confirmed by Northern blot analysis. An enhanced expression of SREBP-1 with an unaltered expression of SREBP-2 in the fasted state (Fig. 2C), and the enhanced expression of its target genes, including the spot 14, ATP citrate-lyase, fatty acid synthase, and malic enzyme gene, in the fasted state was observed in IRS-2-/- mice (Fig. 2D). In addition, RNase protection assay revealed that SREBP-1c expression was up-regulated specifically in IRS-2-/- mice (data not shown). Consistent with these findings, the triglyceride content of IRS-2-/- mouse liver was elevated significantly (Fig. 2E), confirming the physiological significance of an enhanced SREBP-1c expression in IRS-2-/- mice. By contrast, the cholesterol content of IRS-2-/- mouse liver was slightly reduced, consistent with unaltered SREBP-1a and SREBP-2 expression (21).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   Induction of SREBP-1 and its target genes associated with an increased triglyceride content in IRS-2-/- mice liver. A, total RNA isolated from livers of 16-week-old wild-type, IRS-1-/-, and IRS-2-/- mice was analyzed by murine Mu11K oligonucleotide microarray (Affymetrix). The expression levels of SREBP-1 in IRS-1-/- and IRS-2-/- mice were compared with that in wild-type mice, and -fold change of expression in mutant mice versus wild-type mice was calculated using Affymetrix Genechip 3.1 software. B, expression of SREBP-1c target genes in wild-type and IRS-2-/- mice was analyzed, and -fold change of expression was as calculated as described above. C, total RNA was extracted from liver of fasted animals with each genotype at 16 weeks of age. The 20-µg aliquots were subjected to Northern blot hybridization with the indicated 32P-labeled cDNA probes. D, Northern blot analysis for SREBP-1c target genes. FAS, fatty acid synthase. E, livers from 6-week-old animals with each genotype were subjected to triglyceride (TG) and cholesterol (Chol.) content analysis as indicated. WT, wild-type. Values are expressed as means ± S.E. (n = 6). **, p < 0.01 compared with the wild-type. N.S., difference not significant.

SREBP-1 Expression Was Increased in Euglycemic 6-Week-old IRS-2-/- Mice-- Because SREBP-1 expression is reportedly induced by glucose itself (25, 26), we assessed the involvement of hyperglycemia in SREBP-1 gene induction in IRS-2-/- mice. First, we examined the expression of SREBP-1 in the liver of 6-week-old IRS-2-/- mice having normal glucose tolerance and found an elevated expression of SREBP-1 gene (Fig. 3A). Moreover, a comparable increment in SREBP-1 expression was detected in female IRS-2-/- mice, which have better glucose tolerance than male mice (Fig. 3B). Thus, hyperglycemia may not be the cause of the SREBP-1 gene induction.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 3.   SREBP-1 gene induction under normal glucose tolerance. A, total RNA was extracted from liver of fasted wild-type and IRS-2-/- male (A) and female (B) mice at 6 weeks of age, and 20-µg aliquots were subjected to Northern blot hybridization with the 32P-labeled cDNA probes indicated.

Leptin Lowered SREBP-1 Expression in IRS-2-/- Mouse Liver-- Leptin resistance is known to be associated with an increased SREBP-1 gene expression (34). To assess the leptin action in IRS-2-/- mice, we administered the low dose leptin to euglycemic 6-week-old IRS-2-/- mice with increased adiposity and hyperleptinemia (see Fig. 1). The daily intraperitoneal administration of leptin (10 mg/kg body weight per day) was sufficient to reduce food intake and body weight in the wild-type but failed to do so in IRS-2-/- mice (Fig. 4A). Thus, IRS-2-/- mice were leptin-resistant even in the euglycemic stage. Next we examined the effects of higher dose leptin administration. We found that administration of a 50 mg/kg body weight dose to 6-week-old IRS-2-/- mice three times a day resulted in a significant decrease in food intake and body weight gain (Fig. 4B). Moreover, administration of the same amount of leptin into the fasted IRS-2-/- mice resulted in the amelioration of SREBP-1 overexpression (Fig. 4C). Thus, a high dose of leptin administration into leptin-resistant IRS-2-/- mice lowered the increased SREBP-1 expression in the liver.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Leptin lowers SREBP-1 gene expression in IRS-2-/- mice liver. A, leptin resistance in IRS-2-/- mice. Wild-type (WT), IRS-1-/-, and IRS-2-/- mice were injected intraperitoneally with saline or leptin (10 mg/kg/injection) once a day, at 2100 h, and body weight (BW) and food intake were monitored daily at 0900 and 2100 h. Values are expressed as means ± S.E. (n = 9). **, p < 0.01; ***, p < 0.001; N.S., difference not significant. B and C, leptin (Lep) (50 mg/kg/injection) or control saline were administered to 6-week-old IRS-2-/- mice three times a day. Food intake and body weight were monitored (B). Total RNA was extracted from the liver, and 20-µg aliquots were subjected to blot hybridization with the indicated 32P-labeled cDNA probes (C). NS, difference not significant.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have demonstrated an induction of SREBP-1c gene expression in the liver of diabetic insulin-resistant IRS-2-/- mice. This paradoxical finding prompted us to explore factors other than insulin that induced SREBP-1 gene expression in IRS-2-/- mice. We showed that leptin resistance contributes, at least in part, to the up-regulation of the SREBP-1 gene by demonstrating that high dose leptin administration not only reduced food intake and body weight but also ameliorated SREBP-1 overexpression in IRS-2-/- mice. Analogous situations were reported in ob/ob mice, lipoatrophic mice (35, 36), and leptin-unresponsive obese Zucker diabetic fatty fa/fa rats (34), suggesting that leptin resistance is linked causally to SREBP-1 gene induction in liver. We observed further an up-regulated expression of SREBP-1 gene in goldthioglucose-treated leptin-resistant mice,2 indicating that leptin resistance in hypothalamus is involved directly in SREBP-1 gene induction in liver.

How does leptin resistance contribute to increased SREBP-1c gene expression? As leptin reportedly increases glucose uptake and glucose turnover in peripheral tissues, thus decreasing glucose influx into the liver (37), leptin resistance may provoke an increased glucose influx into liver. Because glucose influx into hepatocytes is one of the most important up-regulators of SREBP-1 gene (25, 26), an enhanced liver glucose uptake in leptin-resistant IRS-2-/- mice causes up-regulation of SREBP-1 gene expression, thus causing fatty liver. Our hypothesis that leptin resistance is the cause of SREBP-1 gene induction may explain why fatty liver is commonly observed among insulin-resistant over-nourished obese type 2 diabetes patients with relatively preserved insulin secretory function.

SREBP-1 gene up-regulation may possibly contribute to ameliorating insulin resistance through bypassing the insulin requirement for energy storage by inducing lipogenic and glucokinase genes (22, 23, 31). Increased triglyceride content in the target tissue of insulin, which is the result of SREBP-1 gene up-regulation, was reported to be associated with insulin resistance. We speculate that SREBP-1 gene up-regulation with fatty liver development may be a kind of adaptive response in leptin-resistant over-nourished state, with liver taking up excess energy from blood flow instead of peripheral tissues.

How does leptin resistance in IRS-2-/- mice develop? Our in vitro study showed that lack of IRS-2 had little effect on insulin-stimulated glucose uptake in the isolated adipocytes of IRS-2-/- mice.3 The almost normal insulin function in IRS-2-/- mice adipocytes may cause an increased glucose and lipid uptake by these cells in the presence of hyperinsulinemia, which was provoked by liver-insulin resistance in IRS-2-/- mice, and thus result in the enlargement of adipocytes. In accordance with the observation that adipocyte hypertrophy is associated with leptin resistance in the hypothalamus (38, 39), the obese 6-week-old IRS-2-/- mice showed leptin resistance before developing diabetes (see Fig. 1 and Fig. 4). Alternatively, lack of IRS-2 may influence directly leptin signaling pathways in the hypothalamus, because leptin-stimulated phosphorylation of signal transducers and activators of transcription 3 in the hypothalamus is attenuated in IRS-2-/- mice (40), and because neuron-specific insulin receptor knockout mice showed leptin resistance (41).

    ACKNOWLEDGEMENTS

We are grateful to Dr. Hitoshi Shimano for Northern blot probe of spot 14 and fatty acid synthase. We are grateful to Drs. Hidehiko Furukawa, Nobufusa Serizawa, and Norio Nakamura for supporting the experiments on DNA chips. We thank Dr. Kajuro Komeda, Dr. Mitsuhiko Noda, Dr. Kazuhiro Eto, Dr. Kazuo Hara, Dr. Katsuko Takasawa, Shoji Asai, Dr. Hitoshi Shimano, and Dr. Wataru Ogawa for helpful discussion. We thank G. Yu, A. Nagano, and H. Chiyonobu for excellent technical assistance and mouse husbandry.

    FOOTNOTES

* This work was supported by Health Sciences research grants (for research on human genome and gene therapy) from the Ministry of Health and Welfare and Grant 1-2000-231 from the Juvenile Diabetes Foundation International (to T. K.), by a grant-in-aid for the development of innovative technology and a grant-in-aid for creative basic research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to T. K. and K. T.), and by a health sciences research grant from the Ministry of Health and Welfare (to R. N.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Dept. of Internal Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Tel.: 81-3-5800-8818; Fax: 81-3-5689-7209; E-mail: kadowaki-3im@h.u-tokyo.ac.jp.

Published, JBC Papers in Press, August 23, 2001, DOI 10.1074/jbc.C100160200

2 M. Aoyama, K. Tobe, R. Suzuki, and T. Kadowaki, unpublished observation.

3 S. Satoh, K. Tobe, R. Suzuki, and T. Kadowaki, unpublished observation.

    ABBREVIATIONS

The abbreviations used are: IRS, insulin receptor substrate; SREBP, sterol regulatory element-binding protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Kadowaki, T. (2000) J. Clin. Invest. 106, 459-465[Medline] [Order article via Infotrieve]
2. White, M. F. (1998) Mol. Cell. Biochem. 182, 3-11[CrossRef][Medline] [Order article via Infotrieve]
3. Virkamaki, A., Ueki, K., and Kahn, C. R. (1999) J. Clin. Invest. 103, 931-943[Medline] [Order article via Infotrieve]
4. Keller, S. R., and Lienhard, G. E. (1994) Trends Cell Biol. 4, 115-119[CrossRef][Medline] [Order article via Infotrieve]
5. White, M. F., Maron, R., and Kahn, C. R. (1985) Nature 318, 183-186[CrossRef][Medline] [Order article via Infotrieve]
6. Sun, X. J., Wang, L. M., Zhang, Y., Yenush, L., Myers, M. G., Jr., Glasheen, E., Lane, W. S., Pierce, J. H., and White, M. F. (1995) Nature 377, 173-177[CrossRef][Medline] [Order article via Infotrieve]
7. Lavan, B. E., Lane, W. S., and Lienhard, G. E. (1997) J. Biol. Chem. 272, 11439-11443[Abstract/Free Full Text]
8. Lavan, B. E., Fantin, V. R., Chang, E. T., Lane, W. S., Keller, S. R., and Lienhard, G. E. (1997) J. Biol. Chem. 272, 21403-21407[Abstract/Free Full Text]
9. Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S., Sekihara, H., Yoshioka, S., Horikoshi, H., Furuta, Y., Ikawa, Y., Kasuga, M., Yazaki, Y., and Aizawa, S. (1994) Nature 372, 182-186[CrossRef][Medline] [Order article via Infotrieve]
10. Araki, E., Lipes, M. A., Patti, M. E., Bruning, J. C., Haag, I. B., Johnson, R. S., and Kahn, C. R. (1994) Nature 372, 186-190[CrossRef][Medline] [Order article via Infotrieve]
11. Tobe, K., Tamemoto, H., Yamauchi, T., Aizawa, S., Yazaki, Y., and Kadowaki, T. (1995) J. Biol. Chem. 270, 5698-5701[Abstract/Free Full Text]
12. Yamauchi, T., Tobe, K., Tamemoto, H., Ueki, K., Kaburagi, Y., Yamamoto-Honda, R., Takahashi, Y., Yoshizawa, F., Aizawa, S., Akanuma, Y., Sonenberg, N., Yazaki, Y., and Kadowaki, T. (1996) Mol. Cell. Biol. 16, 3074-3084[Abstract]
13. Terauchi, Y., Iwamoto, K., Tamemoto, H., Komeda, K., Ishii, C., Kanazawa, Y., Asanuma, N., Aizawa, T., Akanuma, Y., Yasuda, K., Kodama, T., Tobe, K., Yazaki, Y., and Kadowaki, T. (1997) J. Clin. Invest. 99, 861-866[Medline] [Order article via Infotrieve]
14. Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., Zhang, Y., Bernal, D., Pons, S., Shulman, G. I., Bonner-Weir, S., and White, M. F. (1998) Nature 391, 900-904[CrossRef][Medline] [Order article via Infotrieve]
15. Withers, D. J., Burks, D. J., Towery, H. H., Altamuro, S. L., Flint, C. L., and White, M. F. (1999) Nat. Genet. 23, 32-40[Medline] [Order article via Infotrieve]
16. Kubota, N., Tobe, K., Terauchi, Y., Eto, K., Yamauchim, T., Tsubamoto, Y., Komeda, K., Takazawa, K., Isogawa, A., Suzuki, R., Nakano, R., Waki, K., Hara, K., Aizawa, S., Noda, M., Akanuma, Y., Nagai, R., Accili, D., Kimura, S., Taylor, S., and Kadowaki, T. (2000) Diabetes 49, 1880-1889[Abstract]
17. Liu, S. C., Wang, Q., Lienhard, G. E., and Keller, S. R. (1999) J. Biol. Chem. 274, 18093-18099[Abstract/Free Full Text]
18. Fantin, V. R., Wang, Q., Lienhard, G. E., and Keller, S. R. (2000) Am. J. Physiol. Endocrinol. Metab. 278, E127-E133[Abstract/Free Full Text]
19. Michael, M. D., Kulkarni, R. N., Postic, C., Previs, S. F., Shulman, G. I., Magnuson, M. A., and Kahn, C. R. (2000) Mol. Cell 6, 87-97[CrossRef][Medline] [Order article via Infotrieve]
20. O'Brien, R. M., and Granner, D. K. (1996) Physiol. Rev. 76, 1109-1161[Abstract/Free Full Text]
21. Brown, M. S., and Goldstein, J. L. (1997) Cell 89, 331-340[CrossRef][Medline] [Order article via Infotrieve]
22. Foretz, M., Guichard, C., Ferre, P., and Foufelle, F. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 12737-12742[Abstract/Free Full Text]
23. Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J. D., Brown, M. S., and Goldstein, J. L. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13656-13661[Abstract/Free Full Text]
24. Kim, J. B., and Spiegelman, B. M. (1996) Genes Dev. 10, 1096-1107[Abstract/Free Full Text]
25. Foretz, M., Pacot, C., Dugail, I., Lemarchand, P., Guichard, C., LeLiepvre, X., Berthelier-Lubrano, C., Spiegelman, B., Kim, J., Ferre, P., and Foufelle, F. (1999) Mol. Cell. Biol. 19, 3760-3768[Abstract/Free Full Text]
26. Shimano, H., Yahagi, N., Amemiya-Kudo, M., Hasty, A. H., Osuga, J., Tamura, Y., Shionoiri, F., Iizuka, Y., Ohashi, K., Harada, K., Gotoda, T., Ishibashi, S., and Yamada, N. (1999) J. Biol. Chem. 274, 35832-35839[Abstract/Free Full Text]
27. Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekihara, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S., Nagai, R., Tobe, K., Kimura, S., and Kadowaki, T. (1999) Mol. Cell 4, 597-609[CrossRef][Medline] [Order article via Infotrieve]
28. Yokode, M., Hammer, R. E., Ishibashi, S., Brown, M. S., and Goldstein, J. L. (1990) Science 250, 1273-1275[Abstract/Free Full Text]
29. Lockhart, D. J., Dong, H., Byrne, M. C., Follettie, M. T., Gallo, M. V., Chee, M. S., Mittmann, M., Wang, C., Kobayashi, M., Horton, H., and Brown, E. L. (1996) Nat. Biotechnol. 14, 1675-1680[CrossRef][Medline] [Order article via Infotrieve]
30. Shimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., and Goldstein, J. L. (1996) J. Clin. Invest. 98, 1575-1584[Medline] [Order article via Infotrieve]
31. Shimano, H., Horton, J. D., Shimomura, I., Hammer, R. E., Brown, M. S., and Goldstein, J. L. (1997) J. Clin. Invest. 99, 846-854[Medline] [Order article via Infotrieve]
32. Shimomura, I., Shimano, H., Horton, J. D., Goldstein, J. L., and Brown, M. S. (1997) J. Clin. Invest. 99, 838-845[Medline] [Order article via Infotrieve]
33. Previs, S. F., Withers, D. J., Ren, J. M., White, M. F., and Shulman, G. I. (2000) J. Biol. Chem. 275, 38990-38994[Abstract/Free Full Text]
34. Kakuma, T., Lee, Y., Higa, M., Wang, Z., Pan, W., Shimomura, I., and Unger, R. H. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 8536-8541[Abstract/Free Full Text]
35. Shimomura, I., Bashmakov, Y., and Horton, J. D. (1999) J. Biol. Chem. 274, 30028-30032[Abstract/Free Full Text]
36. Shimomura, I., Matsuda, M., Hammer, R. E., Bashmakov, Y., Brown, M. S., and Goldstein, J. L. (2000) Mol. Cell 6, 77-86[CrossRef][Medline] [Order article via Infotrieve]
37. Kamohara, S., Burcelin, R., Halaas, J. L., Friedman, J. M., and Charron, M. J. (1997) Nature 389, 374-377[CrossRef][Medline] [Order article via Infotrieve]
38. Spiegelman, B. M., and Flier, J. S. (1996) Cell 87, 377-389[CrossRef][Medline] [Order article via Infotrieve]
39. Marsh, D. J., Hollopeter, G., Huszar, D., Laufer, R., Yagaloff, K. A., and Fish, S. I. (1999) Nat. Genet. 21, 119-122[CrossRef][Medline] [Order article via Infotrieve]
40. Burks, D. J., Font de Mora, J., Schubert, M., Withers, D. J., Myers, M. G., Towery, H. H., Altamuro, S. L., Flint, C. L., and White, M. F. (2000) Nature 407, 377-382[CrossRef][Medline] [Order article via Infotrieve]
41. Bruning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Muller-Wieland, D., and Kahn, C. R. (2000) Science 289, 2122-2125[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Erhuma, A. M. Salter, D. V. Sculley, S. C. Langley-Evans, and A. J. Bennett
Prenatal exposure to a low-protein diet programs disordered regulation of lipid metabolism in the aging rat
Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1702 - E1714.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Kamei, K. Tobe, R. Suzuki, M. Ohsugi, T. Watanabe, N. Kubota, N. Ohtsuka-Kowatari, K. Kumagai, K. Sakamoto, M. Kobayashi, et al.
Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin Resistance
J. Biol. Chem., September 8, 2006; 281(36): 26602 - 26614.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. B. Biddinger, M. Miyazaki, J. Boucher, J. M. Ntambi, and C. R. Kahn
Leptin Suppresses Stearoyl-CoA Desaturase 1 by Mechanisms Independent of Insulin and Sterol Regulatory Element-Binding Protein-1c.
Diabetes, July 1, 2006; 55(7): 2032 - 2041.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
H. Wang, G. Kouri, and C. B. Wollheim
ER stress and SREBP-1 activation are implicated in {beta}-cell glucolipotoxicity
J. Cell Sci., September 1, 2005; 118(17): 3905 - 3915.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
T. Jiang, S. E. Liebman, M. S. Lucia, C. L. Phillips, and M. Levi
Calorie Restriction Modulates Renal Expression of Sterol Regulatory Element Binding Proteins, Lipid Accumulation, and Age-Related Renal Disease
J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2385 - 2394.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S.-S. Im, S.-Y. Kang, S.-Y. Kim, H.-i. Kim, J.-W. Kim, K.-S. Kim, and Y.-H. Ahn
Glucose-Stimulated Upregulation of GLUT2 Gene Is Mediated by Sterol Response Element-Binding Protein-1c in the Hepatocytes
Diabetes, June 1, 2005; 54(6): 1684 - 1691.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Suzuki, K. Tobe, M. Aoyama, K. Sakamoto, M. Ohsugi, N. Kamei, S. Nemoto, A. Inoue, Y. Ito, S. Uchida, et al.
Expression of DGAT2 in White Adipose Tissue Is Regulated by Central Leptin Action
J. Biol. Chem., February 4, 2005; 280(5): 3331 - 3337.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
A M Diehl, Z P Li, H Z Lin, and S Q Yang
Cytokines and the pathogenesis of non-alcoholic steatohepatitis
Gut, February 1, 2005; 54(2): 303 - 306.
[Full Text] [PDF]


Home page
DiabetesHome page
Y. Terauchi, J. Matsui, J. Kamon, T. Yamauchi, N. Kubota, K. Komeda, S. Aizawa, Y. Akanuma, M. Tomita, and T. Kadowaki
Increased Serum Leptin Protects From Adiposity Despite the Increased Glucose Uptake in White Adipose Tissue in Mice Lacking p85{alpha} Phosphoinositide 3-Kinase
Diabetes, September 1, 2004; 53(9): 2261 - 2270.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Suzuki, K. Tobe, M. Aoyama, A. Inoue, K. Sakamoto, T. Yamauchi, J. Kamon, N. Kubota, Y. Terauchi, H. Yoshimatsu, et al.
Both Insulin Signaling Defects in the Liver and Obesity Contribute to Insulin Resistance and Cause Diabetes in Irs2-/- Mice
J. Biol. Chem., June 11, 2004; 279(24): 25039 - 25049.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. Ahluwalia, K. H. Clodfelter, and D. J. Waxman
Sexual Dimorphism of Rat Liver Gene Expression: Regulatory Role of Growth Hormone Revealed by Deoxyribonucleic Acid Microarray Analysis
Mol. Endocrinol., March 1, 2004; 18(3): 747 - 760.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
T. Matsuzaka, H. Shimano, N. Yahagi, M. Amemiya-Kudo, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, S. Tomita, M. Sekiya, et al.
Insulin-Independent Induction of Sterol Regulatory Element-Binding Protein-1c Expression in the Livers of Streptozotocin-Treated Mice
Diabetes, March 1, 2004; 53(3): 560 - 569.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Shimizu, S. Ugi, H. Maegawa, K. Egawa, Y. Nishio, T. Yoshizaki, K. Shi, Y. Nagai, K. Morino, K.-i. Nemoto, et al.
Protein-tyrosine Phosphatase 1B as New Activator for Hepatic Lipogenesis via Sterol Regulatory Element-binding Protein-1 Gene Expression
J. Biol. Chem., October 31, 2003; 278(44): 43095 - 43101.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Wang, P. Maechler, P. A. Antinozzi, L. Herrero, K. A. Hagenfeldt-Johansson, A. Bjorklund, and C. B. Wollheim
The Transcription Factor SREBP-1c Is Instrumental in the Development of beta -Cell Dysfunction
J. Biol. Chem., May 2, 2003; 278(19): 16622 - 16629.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
T. Akune, N. Ogata, K. Hoshi, N. Kubota, Y. Terauchi, K. Tobe, H. Takagi, Y. Azuma, T. Kadowaki, K. Nakamura, et al.
Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts
J. Cell Biol., October 14, 2002; 159(1): 147 - 156.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. M. Rondinone, J. M. Trevillyan, J. Clampit, R. J. Gum, C. Berg, P. Kroeger, L. Frost, B. A. Zinker, R. Reilly, R. Ulrich, et al.
Protein Tyrosine Phosphatase 1B Reduction Regulates Adiposity and Expression of Genes Involved in Lipogenesis
Diabetes, August 1, 2002; 51(8): 2405 - 2411.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
L. M. Scearce, J. E. Brestelli, S. K. McWeeney, C. S. Lee, J. Mazzarelli, D. F. Pinney, A. Pizarro, C. J. Stoeckert Jr., S. W. Clifton, M. A. Permutt, et al.
Functional Genomics of the Endocrine Pancreas: The Pancreas Clone Set and PancChip, New Resources for Diabetes Research
Diabetes, July 1, 2002; 51(7): 1997 - 2004.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Sun, S. Liu, S. Ferguson, L. Wang, P. Klepcyk, J. S. Yun, and J. E. Friedman
Phosphoenolpyruvate Carboxykinase Overexpression Selectively Attenuates Insulin Signaling and Hepatic Insulin Sensitivity in Transgenic Mice
J. Biol. Chem., June 21, 2002; 277(26): 23301 - 23307.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. Soulet and S. Rivest
Perspective: How to Make Microarray, Serial Analysis of Gene Expression, and Proteomic Relevant to Day-to-Day Endocrine Problems and Physiological Systems
Endocrinology,